Minimal residual disease evaluation in childhood acute lymphoblastic leukemia: OHTAC recommendation
Health Quality Ontario
Record ID 32016000561
English
Authors' recommendations:
The Ontario Health Technology Advisory Committee recommends publicly funding minimal residual disease evaluation for pediatric management of acute lymphoblastic leukemia.
The Ontario Health Technology Advisory Committee accepted the findings of the clinical and economic assessments, and decided to recommend in favour of public funding.
Details
Project Status:
Completed
Year Published:
2016
URL for published report:
http://www.hqontario.ca/Portals/0/documents/eds/ohtas/recommendation-mrd-1603-en.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Humans
- Neoplasm, Residual
- Precursor Cell Lymphoblastic Leukemia-Lymphoma
Contact
Organisation Name:
Health Quality Ontario
Contact Address:
Evidence Development and Standards, Health Quality Ontario, 130 Bloor Street West, 10th floor, Toronto, Ontario Canada M5S 1N5
Contact Name:
EDSinfo@hqontario.ca
Contact Email:
OH-HQO_hta-reg@ontariohealth.ca
Copyright:
Health Quality Ontario (HQO)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.